Cassava Sciences (Cassava Sciences) YoY EBITDA Growth

: -5.56% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Cassava Sciences's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was -5.56%.

Cassava Sciences's EBITDA per Share for the three months ended in Dec. 2023 was $-0.53.

Cassava Sciences YoY EBITDA Growth Historical Data

The historical data trend for Cassava Sciences's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cassava Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

54.46

7.83

-216.99

-138.49

-27.17

Cassava Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
YoY EBITDA Growth																-42.37	-42.92	-38.57	-24.57	-5.56

Cassava Sciences YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Cassava Sciences's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-2.49	-	-1.958)	/	\| -1.958 \|
=	-27.17 %

Cassava Sciences's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2023 )
=	(EBITDA per Share (Q: Dec. 2023 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(-0.532	-	-0.504)	/	\| -0.504 \|
=	-5.56 %

Cassava Sciences YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Cassava Sciences's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Cassava Sciences (Cassava Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cassava Sciences Inc (NAS:SAVA) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

SAVA:Mexico PX91:Germany PX91:Germany

Address

6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731

Website

https://www.cassavasciences.com

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.

Executives

Sanford Robertson	director	ONE LETTERMAN DRIVE, BUILDING C SUITE 410, SAN FRANCISCO CA 94129
Richard Barry	director	285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Robert Christopher Cook	officer: SVP & General Counsel	6801 N. CAPITAL OF TEXAS HWY, BUILDING 1, SUITE 300, AUSTIN TX 78731
James William Kupiec	officer: Chief Clinical Dev. Officer	7801 N CAPITAL OF TEXAS HIGHWAY, SUITE 260, AUSTIN TX 78731
Eric Schoen	officer: Chief Financial Officer	7801 N. CAPITAL OF TX HWY, SUITE 260, AUSTIN TX 78731
Remi Barbier	director, 10 percent owner, officer: CEO, Chairman of the Board
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
O Donnell Michael J	director
Robert Z Gussin	director
Scannon Patrick J Md Phd	director	C/O XOMA, LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
Saira Ramasastry	director	501 CANAL BLVD., RICHMOND CA 94804
Nadav Friedmann	director, officer: Chief Scientific Officer
Sabretooth Master Fund, L.p.	10 percent owner	405 LEXINGTON AVENUE, 50TH FLOOR, NEW YORK NY 10174